The FDA has approved Astellas’s zolbetuximab (Vyloy) for HER2-negative, claudin-18.2 (CLDN18.2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. It is the first CLDN18.2-targeted ...
Gastric cancer is a beast. Despite being the fourth most fatal cancer worldwide — killing nearly 770,000 people per year — drug developers have made little headway against it in decades. For most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback